Trials / Terminated
TerminatedNCT02646774
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of intravenous micafungin for the treatment of proven or probable fungal infections caused by Aspergillus sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | Injection |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-06-26
- Completion
- 2015-06-26
- First posted
- 2016-01-06
- Last updated
- 2024-11-20
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02646774. Inclusion in this directory is not an endorsement.